Abstract 8509

Article

R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma followed by autologous stem cell transplantation: CORAL study

R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma followed by autologous stem cell transplantation: CORAL study

C. Gisselbrecht, B. Glass, N. Mounier, et al

Methods: This randomized Intergroup trial compared rituximab (Rituxan) with ifosfamide, etoposide, carboplatin (R-ICE) and rituximab with dexamethasone aracytine and cisplatin (R-DHAP) in DLBCL CD 20+ patients in their first relapse or refractory to first-line therapy. Responding patients received BEAM (carmustine, cytarabine, etoposide, and melphalan) and ASCT and were then randomized to observation or rituximab for 1 year.

Results: Patients with prior exposure to rituximab had more refractory disease and adverse prognostic factors. An intent-to-treat analysis of the first patients (median age 55) showed an ORR of 63%, with 38% in complete remission, with no differences between the ORR for R-ICE (63.5%) and R-DHAP (62.8%) or in mobilization adjusted response rates. Factors significantly affecting response rate (P < .0001) were refractory/relapse < 12 months (46% vs 88%), secondary IPI >1 (52% vs 71%) and prior exposure to rituximab (51% vs 83%).

Conclusions: R-ICE and R-DHAP were similarly effective. A response rate > 80% was observed in patients without adverse prognostic factors. However, patients with early relapses/ refractory after up-front rituximab-based chemotherapy had a poor response rate and prognosis. Longer follow-up is necessary to evaluate the second randomization.

Recent Videos
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Related Content